Pulmonary hypertension in left heart disease: The need to continue to explore

Affiliations

¹ Dept. of Cardiology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy. Electronic address: s.ghio@smatteo.pv.it.
² Dept. of Cardiology, University "L. Vanvitelli" - Monaldi Hospital, Naples, Italy.
³ Pulmonary Hypertension Unit, Dept. of Cardiovascular and Respiratory Science, "Sapienza" University of Rome, Italy.

Editorial

Stefano Ghio et al. Int J Cardiol. 2019.

. 2019 Aug 1:288:132-134.

doi: 10.1016/j.ijcard.2019.03.027. Epub 2019 Mar 17.

¹ Dept. of Cardiology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy. Electronic address: s.ghio@smatteo.pv.it.
² Dept. of Cardiology, University "L. Vanvitelli" - Monaldi Hospital, Naples, Italy.
³ Pulmonary Hypertension Unit, Dept. of Cardiovascular and Respiratory Science, "Sapienza" University of Rome, Italy.

No abstract available

Comment on

Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: A meta-analysis.
Cao JY, Wales KM, Cordina R, Lau EMT, Celermajer DS. Cao JY, et al. Int J Cardiol. 2018 Dec 15;273:213-220. doi: 10.1016/j.ijcard.2018.09.043. Epub 2018 Sep 12. Int J Cardiol. 2018. PMID: 30224253
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Kramer T, Dumitrescu D, Gerhardt F, Orlova K, Ten Freyhaus H, Hellmich M, Baldus S, Rosenkranz S. Kramer T, et al. Int J Cardiol. 2019 May 15;283:152-158. doi: 10.1016/j.ijcard.2018.12.078. Epub 2019 Jan 4. Int J Cardiol. 2019. PMID: 30777406